NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

The RH5.1/Matrix-M malaria vaccine, studied in a Phase IIb trial, shows 55% efficacy against clinical malaria and over 80% against severe disease, with favorable safety and tolerability. It could complement existing pre-erythrocytic vaccines, offering a second line of defense against malaria.

Soligenix opens patient enrollment for FLASH2 Phase 3 study evaluating HyBryte™ for cutaneous T-cell lymphoma (CTCL), building on previous successful studies. The study aims to demonstrate HyBryte™'s efficacy over 18 weeks of continuous treatment, with interim analysis expected in early 2026.

Soligenix, Inc. initiates patient enrollment for FLASH2, a Phase 3 study on HyBryteTM for treating cutaneous T-cell lymphoma (CTCL). Building on previous successful trials, FLASH2 aims to confirm HyBryte's efficacy and safety over 18 weeks of continuous treatment, offering a promising alternative for early-stage CTCL patients.

A.F., M.E.S., S.R.W., C.M.E., N.R., C.L.G., K.L.K., J.A.G., E.A.H., and M.D.T. disclosed various research grants, advisory board fees, and institutional funding from pharmaceutical companies and NIH/NIAID, indicating potential conflicts of interest relevant to the manuscript's content.

NIH has reallocated $147 million to the RECOVER Initiative, bringing total new funding to $662 million. This supports ongoing research, including clinical trials, observational studies, and pathobiology studies, aiming to understand and treat long COVID. RECOVER-TLC, a new program, will focus on long COVID clinical trials, engaging with patients and researchers. Additional pathobiology awards will examine biological mechanisms and tissue-specific manifestations of long COVID.

Tecovirimat showed no efficacy in reducing lesion resolution time or pain in mild to moderate clade II mpox cases, leading to halted enrollment in the STOMP trial. No safety issues were noted. The study emphasizes the need for randomized trials in outbreak responses and continues to explore mpox treatments.

Tecovirimat showed no efficacy in reducing lesion resolution time or pain in adults with mild to moderate clade II mpox, leading to halted enrollment in the STOMP trial. No safety concerns were noted. The study underscores the importance of clinical trials for mpox countermeasures, with ongoing research for effective treatments.

A study led by Dr. Kristen Marks found HepB-CpG vaccine induced protective antibodies in 99.4% of HIV-positive individuals who didn't respond to prior vaccination, compared to 80.6% with HepB-alum. HepB-CpG is preferred for boosting hepatitis B immunity in HIV-positive adults.

The NIH's STOMP trial found tecovirimat (TPOXX) safe but ineffective for improving lesion resolution or pain relief in mild to moderate mpox cases. The study, halted early, involved participants from multiple countries. Tecovirimat remains available through the CDC's expanded access program for severe cases.

Tecovirimat showed no reduction in lesion resolution time or pain for mild to moderate clade II mpox patients, leading to halted enrollment in its trial. No safety concerns were noted. The study underscores the importance of clinical trials during outbreaks, with ongoing research for mpox treatments.